Immunomodulation by Mesenchymal Stem Cells
暂无分享,去创建一个
Mohamed H. Sayegh | Mark Atkinson | Reza Abdi | M. Atkinson | R. Abdi | P. Fiorina | C. Adra | M. Sayegh | Chaker N. Adra | Paolo Fiorina
[1] K. Okumura,et al. The Impact of the Capability of Circulating Progenitor Cell to Differentiate on Myocardial Salvage in Patients With Primary Acute Myocardial Infarction , 2006, Circulation.
[2] Giselle Chamberlain,et al. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing , 2007, Stem cells.
[3] P. Bianco,et al. Marrow stromal stem cells. , 2000, The Journal of clinical investigation.
[4] L. Mazzini,et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis , 2006, Neurological research.
[5] Lindolfo da Silva Meirelles,et al. Mesenchymal stem cells reside in virtually all post-natal organs and tissues , 2006, Journal of Cell Science.
[6] Elizabeth Simpson,et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.
[7] Darwin J. Prockop,et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice , 2006, Proceedings of the National Academy of Sciences.
[8] N. Sasaki,et al. Mesenchymal Stem Cells Facilitate the Induction of Mixed Hematopoietic Chimerism and Islet Allograft Tolerance without GVHD in the Rat , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] Sergio Romagnani,et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.
[10] L. Moretta,et al. Mesenchymal stem cells inhibit natural killer – cell proliferation , cytotoxicity , and cytokine production : role of indoleamine 2 , 3-dioxygenase and prostaglandin E 2 , 2008 .
[11] M. Atkinson,et al. Why can't we prevent type 1 diabetes?: maybe it's time to try a different combination. , 2003, Diabetes care.
[12] L. Hsiao,et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. , 2005, The Journal of clinical investigation.
[13] M. Kay,et al. Sarcoma Derived from Cultured Mesenchymal Stem Cells , 2007, Stem cells.
[14] R. Willemze,et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. , 2006, Blood.
[15] J. Mosca,et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. , 2005, Journal of biomedical science.
[16] Mark S. Anderson,et al. The NOD mouse: a model of immune dysregulation. , 2005, Annual review of immunology.
[17] O. Ringdén,et al. Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.
[18] Frank P Barry,et al. Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.
[19] A. Friedenstein,et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.
[20] L. Ortiz,et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.
[21] Kazuya Sato,et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.
[22] R. Yañez,et al. Adipose Tissue‐Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft‐Versus‐Host Disease , 2006, Stem cells.
[23] H. Kiem,et al. Comparison of Mesenchymal Stem Cells from Different Tissues to Suppress T-Cell Activation , 2007, Cell transplantation.
[24] S. Ikehara. A novel strategy for allogeneic stem cell transplantation: perfusion method plus intra-bone marrow injection of stem cells. , 2003, Experimental hematology.
[25] O. Ringdén,et al. Immunomodulation by mesenchymal stem cells and clinical experience , 2007, Journal of internal medicine.
[26] G. Mancardi,et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.
[27] L. Moretta,et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. , 2008, Blood.
[28] A. Friedenstein,et al. Osteogenesis in transplants of bone marrow cells. , 1966, Journal of embryology and experimental morphology.
[29] Giselle Chamberlain,et al. Recent advances into the understanding of mesenchymal stem cell trafficking , 2007, British journal of haematology.
[30] G. Sale,et al. Bilateral diffuse pulmonary ectopic ossification after marrow allograft in a dog. Evidence for allotransplantation of hemopoietic and mesenchymal stem cells. , 1983, Experimental hematology.
[31] E. Guinan,et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.
[32] Ulrich Göbel,et al. bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .
[33] N. Wulffraat,et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005 , 2007, Arthritis research & therapy.
[34] V. Starnes,et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection , 2003, Transplantation.
[35] S. E. Jacobsen,et al. Potential risks of bone marrow cell transplantation into infarcted hearts. , 2007, Blood.
[36] Q. Han,et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. , 2005, DNA and cell biology.
[37] N. Perico,et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. , 2004, Journal of the American Society of Nephrology : JASN.
[38] D. Atsma,et al. Opportunities and challenges for mesenchymal stem cell-mediated heart repair , 2007, Current opinion in lipidology.
[39] O. Ringdén,et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.
[40] W. Fibbe. Mesenchymal stem cells. A potential source for skeletal repair , 2002, Annals of the rheumatic diseases.
[41] A. Nauta,et al. Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.
[42] O. Ringdén,et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.
[43] S. Perez,et al. Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.
[44] Hanns-Ulrich Marschall,et al. Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.
[45] F. Benvenuto,et al. Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.
[46] D. Prockop. Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues , 1997, Science.
[47] G. Koehl,et al. Immunomodulatory Effects of Mesenchymal Stem Cells in a Rat Organ Transplant Model , 2006, Transplantation.
[48] J. Rossignol,et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. , 2007, Blood.
[49] R. Cancedda,et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway , 2005, European journal of immunology.
[50] M. Yarmush,et al. Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure , 2007, PloS one.
[51] N. Rouas-Freiss,et al. Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.
[52] Guosheng Lin,et al. Anti-Inflammation Role for Mesenchymal Stem Cells Transplantation in Myocardial Infarction , 2007, Inflammation.
[53] M. Pittenger,et al. Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.
[54] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[55] R. Cancedda,et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. , 2007, Arthritis and rheumatism.
[56] Kevin McIntosh,et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.
[57] G. Sukhikh,et al. Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.
[58] Antonio Uccelli,et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis , 2007, Annals of neurology.
[59] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[60] Jae W. Lee,et al. Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.
[61] T. Nagasawa,et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. , 2006, Immunity.
[62] S. Gerson,et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH) , 2002, Bone Marrow Transplantation.
[63] F. Marini,et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.